Table 1 Baseline characteristics of patients.
Variables | Major adverse cardiovascular events (n = 10) | No major adverse cardiovascular events (n = 27) | P |
|---|---|---|---|
Age, median with range (yr.) | 69 (51–90) | 71 (42–87) | 0.625 |
Sex, male (%) | 5 (50.0%) | 20 (74.1%) | 0.240 |
Comorbidities, n (%) | |||
Hypertension | 8 (80.0%) | 19 (70.4%) | 0.694 |
Diabetes mellitus | 4 (40.0%) | 8 (29.6%) | 0.696 |
Coronary artery disease | 6 (60.0%) | 4 (14.8%) | 0.012 |
Stroke | 5 (50.0%) | 4 (14.8%) | 0.041 |
Atrial fibrillation | 5 (50.0%) | 6 (22.2%) | 0.125 |
Chronic kidney disease | 1 (10.0%) | 3 (11.1%) | 0.528 |
Smoking, n (%) | |||
Current | 2 (20.0%) | 7 (25.9%) | 0.064 |
Ex-smoker | 1 (10.0%) | 12 (44.4%) | |
Never | 7 (70.0%) | 8 (29.6%) | |
Anticoagulation at admission | 2 (20.0%) | 4 (14.8%) | 0.663 |
Antiplatelet agent at admission | 5 (50%) | 13 (48.1%) | 0.666 |
Statin at admission | 3 (30.0%) | 7 (25.9%) | 0.999 |
Clinical manifestation | |||
Intermittent claudication | 2 (20.0%) | 13 (48.1%) | 0.208 |
CLTI | 8 (80%) | 14 (51.9%) | |
Ankle-brachial index, index limb | 0.46 (0–0.49) | 0.54 (0–0.72) | 0.082 |
Adjunctive procedure | |||
Balloon angioplasty | 0 | 2 (7.4%) | 0.839 |
Stent insertion | 1 (10.0%) | 3 (11.1%) | |
Bypass surgery | 1 (10.0%) | 2 (7.4%) | |
Operation time, (min.) | 95 (45–470) | 180 (70–575) | 0.180 |
Hospital stay, (days) | 15 (3–89) | 9 (4–117) | 0.749 |
Antithrombotics after operation | |||
Anticoagulant | 3 (30.0%) | 5 (18.5%) | 0.208 |
Single antiplatelet agent | 3 (30.0%) | 2 (7.4%) | |
Dual antiplatelet agents | 3 (30.0%) | 16 (59.3%) | |
Anticoagulant and antiplatelet agent | 1 (10.0%) | 4 (14.8%) | |
Laboratory findings | |||
Total cholesterol (mg/dL) | 135 (88–278) | 169.5 (94–294) | 0.288 |
hs-CRP (mg/dL) | 0.8 (0.3–4.6) | 1.3 (0.13–52.1) | 0.556 |
Neutrophil (μL) | 3488 (2200–11,719) | 4300 (249–12,050) | 0.494 |
